Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 16/20 | 0.68 |
| ▸ | LIMK1 | P53667 | 5/20 | 0.50 |
| ▸ | AURKA | O14965 | 4/20 | 0.50 |
| ▸ | PLK4 | O00444 | 3/20 | 0.50 |
| ▸ | DYRK3 | O43781 | 3/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.50 |
| ▸ | AXL | P30530 | 3/20 | 0.50 |
| ▸ | FLT4 | P35916 | 3/20 | 0.50 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.50 |
| ▸ | CLK2 | P49760 | 3/20 | 0.50 |
| ▸ | IRAK1 | P51617 | 3/20 | 0.50 |
| ▸ | NEK2 | P51955 | 3/20 | 0.50 |
| ▸ | CSNK1G2 | P78368 | 3/20 | 0.50 |
| ▸ | MAP4K2 | Q12851 | 3/20 | 0.50 |
| ▸ | CAMK2B | Q13554 | 3/20 | 0.50 |
| ▸ | CAMK2G | Q13555 | 3/20 | 0.50 |
| ▸ | CAMK2D | Q13557 | 3/20 | 0.50 |
| ▸ | HIPK4 | Q8NE63 | 3/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.50 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4465809 | 0.82 | PIK3CD (0.49) | KDRLIMK1AURKAPLK4DYRK3 | |
| SCHEMBL4479287 | 0.81 | KDR (1.00) | KDRLIMK1AURKAPLK4DYRK3 | |
| SCHEMBL4467289 | 0.78 | KDR (0.63) | KDRLIMK1AURKAPLK4DYRK3 | |
| SCHEMBL4485278 | 0.78 | KDR (0.68) | KDRLIMK1AURKAPLK4DYRK3 | |
| SCHEMBL4481786 | 0.78 | KDR (0.68) | KDRLIMK1AURKAPLK4DYRK3 | |
| SCHEMBL4482336 | 0.77 | KDR (0.81) | KDRLIMK1AURKAPLK4DYRK3 | |
| SCHEMBL4466605 | 0.76 | KDR (0.77) | KDRLIMK1AURKAPLK4DYRK3 | |
| SCHEMBL4483044 | 0.76 | KDR (0.78) | KDRLIMK1AURKAPLK4DYRK3 | |
| SCHEMBL4468384 | 0.76 | KDR (0.64) | KDRLIMK1AURKAPLK4DYRK3 | |
| SCHEMBL4466053 | 0.74 | KDR (0.61) | KDRLIMK1AURKAKITTEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1487841-B1 | THIOPYRIMIDINE AND ISOTHIAZOLOPYRIMIDINE KINASE INHIBITORS | ABBVIE INC (US) | 2014-01-15 | — | — | EP | disclosed |
| US-7560552-B2 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABBOTT LABORATORIES (US) | 2009-07-14 | — | — | US | disclosed |
| US-20060276490-A1 | Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors | MICHAELIDES MICHAEL R | 2006-12-07 | — | — | US | disclosed |
| US-20040014756-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABBVIE INC. | 2004-01-22 | — | — | US | disclosed |
| US-20030225273-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABBOTT LABORATORIES | 2003-12-04 | — | — | US | disclosed |
| US-20030181468-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABBOTT LABORATORIES | 2003-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014756-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABL1, ERBB2, LCK | KDR 425/4885LIMK1 667/4885AURKA 279/4885 |
| US-20060276490-A1 | Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors | ABL1, LCK, ERBB2 | KDR 391/4885LIMK1 789/4885AURKA 272/4885 |
| US-20030225273-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABL1, ERBB2, LCK | KDR 425/4885LIMK1 667/4885AURKA 279/4885 |
| US-20030181468-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABL1, ERBB2, LCK | KDR 462/4885LIMK1 660/4885AURKA 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.